🇺🇸 FDA
Patent

US 11034672

Tyrosine kinase inhibitor compositions, methods of making and methods of use

granted A61PA61P35/00

Quick answer

US patent 11034672 (Tyrosine kinase inhibitor compositions, methods of making and methods of use) held by Black Diamond Therapeutics, Inc. expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Black Diamond Therapeutics, Inc.
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P35/00